117 related articles for article (PubMed ID: 38537875)
1. NDRG2 acts as a negative regulator of the progression of small-cell lung cancer through the modulation of the PTEN-AKT-mTOR signalling cascade.
Ma Z; Ma Y; Feng J; Xu Z; Cheng C; Qin J; Li S; Jiang J; Kong R
Toxicol Appl Pharmacol; 2024 Apr; 485():116915. PubMed ID: 38537875
[TBL] [Abstract][Full Text] [Related]
2. miR-205 targets PTEN and PHLPP2 to augment AKT signaling and drive malignant phenotypes in non-small cell lung cancer.
Cai J; Fang L; Huang Y; Li R; Yuan J; Yang Y; Zhu X; Chen B; Wu J; Li M
Cancer Res; 2013 Sep; 73(17):5402-15. PubMed ID: 23856247
[TBL] [Abstract][Full Text] [Related]
3. Alpha1-ACT Functions as a Tumour Suppressor in Hepatocellular Carcinoma by Inhibiting the PI3K/AKT/mTOR Signalling Pathway via Activation of PTEN.
Zhu H; Liu Q; Tang J; Xie Y; Xu X; Huang R; Zhang Y; Jin K; Sun B
Cell Physiol Biochem; 2017; 41(6):2289-2306. PubMed ID: 28456796
[TBL] [Abstract][Full Text] [Related]
4. Activation of the PI3K/mTOR Pathway following PARP Inhibition in Small Cell Lung Cancer.
Cardnell RJ; Feng Y; Mukherjee S; Diao L; Tong P; Stewart CA; Masrorpour F; Fan Y; Nilsson M; Shen Y; Heymach JV; Wang J; Byers LA
PLoS One; 2016; 11(4):e0152584. PubMed ID: 27055253
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA-92a promotes epithelial-mesenchymal transition through activation of PTEN/PI3K/AKT signaling pathway in non-small cell lung cancer metastasis.
Lu C; Shan Z; Hong J; Yang L
Int J Oncol; 2017 Jul; 51(1):235-244. PubMed ID: 28534966
[TBL] [Abstract][Full Text] [Related]
6. MiR-181a-5p facilitates proliferation, invasion, and glycolysis of breast cancer through NDRG2-mediated activation of PTEN/AKT pathway.
Zhai Z; Mu T; Zhao L; Li Y; Zhu D; Pan Y
Bioengineered; 2022 Jan; 13(1):83-95. PubMed ID: 34951340
[TBL] [Abstract][Full Text] [Related]
7. Loss of NDRG2 expression activates PI3K-AKT signalling via PTEN phosphorylation in ATLL and other cancers.
Nakahata S; Ichikawa T; Maneesaay P; Saito Y; Nagai K; Tamura T; Manachai N; Yamakawa N; Hamasaki M; Kitabayashi I; Arai Y; Kanai Y; Taki T; Abe T; Kiyonari H; Shimoda K; Ohshima K; Horii A; Shima H; Taniwaki M; Yamaguchi R; Morishita K
Nat Commun; 2014 Feb; 5():3393. PubMed ID: 24569712
[TBL] [Abstract][Full Text] [Related]
8. Correlation between quantitative perfusion histogram parameters of DCE-MRI and PTEN, P-Akt and m-TOR in different pathological types of lung cancer.
Zhang B; Zhao Z; Huang Y; Mao H; Zou M; Wang C; Yu G; Zhang M
BMC Med Imaging; 2021 Apr; 21(1):73. PubMed ID: 33865336
[TBL] [Abstract][Full Text] [Related]
9. Targeting AXL and mTOR Pathway Overcomes Primary and Acquired Resistance to WEE1 Inhibition in Small-Cell Lung Cancer.
Sen T; Tong P; Diao L; Li L; Fan Y; Hoff J; Heymach JV; Wang J; Byers LA
Clin Cancer Res; 2017 Oct; 23(20):6239-6253. PubMed ID: 28698200
[No Abstract] [Full Text] [Related]
10. Human Schlafen 5 Inhibits Proliferation and Promotes Apoptosis in Lung Adenocarcinoma via the PTEN/PI3K/AKT/mTOR Pathway.
Gu X; Zhou L; Chen L; Pan H; Zhao R; Guang W; Wan G; Zhang P; Liu D; Deng LL; Zhao W; Lu C
Biomed Res Int; 2021; 2021():6628682. PubMed ID: 33860045
[TBL] [Abstract][Full Text] [Related]
11. NDRG2 suppresses proliferation, migration, invasion and epithelial-mesenchymal transition of esophageal cancer cells through regulating the AKT/XIAP signaling pathway.
Yang CL; Zheng XL; Ye K; Ge H; Sun YN; Lu YF; Fan QX
Int J Biochem Cell Biol; 2018 Jun; 99():43-51. PubMed ID: 29530788
[TBL] [Abstract][Full Text] [Related]
12. FGFRL1 affects chemoresistance of small-cell lung cancer by modulating the PI3K/Akt pathway via ENO1.
Chen R; Li D; Zheng M; Chen B; Wei T; Wang Y; Li M; Huang W; Tong Q; Wang Q; Zhu Y; Fang W; Guo L; Fang S
J Cell Mol Med; 2020 Feb; 24(3):2123-2134. PubMed ID: 31957179
[TBL] [Abstract][Full Text] [Related]
13. MYC-Driven Small-Cell Lung Cancer is Metabolically Distinct and Vulnerable to Arginine Depletion.
Chalishazar MD; Wait SJ; Huang F; Ireland AS; Mukhopadhyay A; Lee Y; Schuman SS; Guthrie MR; Berrett KC; Vahrenkamp JM; Hu Z; Kudla M; Modzelewska K; Wang G; Ingolia NT; Gertz J; Lum DH; Cosulich SC; Bomalaski JS; DeBerardinis RJ; Oliver TG
Clin Cancer Res; 2019 Aug; 25(16):5107-5121. PubMed ID: 31164374
[TBL] [Abstract][Full Text] [Related]
14. Suppression of HELLS by miR-451a represses mTOR pathway to hinder aggressiveness of SCLC.
Cui J; Wang J; Shen Y; Lin D
Genes Genomics; 2021 Feb; 43(2):105-114. PubMed ID: 33460027
[TBL] [Abstract][Full Text] [Related]
15. Upregulated TRIM29 promotes proliferation and metastasis of nasopharyngeal carcinoma via PTEN/AKT/mTOR signal pathway.
Zhou XM; Sun R; Luo DH; Sun J; Zhang MY; Wang MH; Yang Y; Wang HY; Mai SJ
Oncotarget; 2016 Mar; 7(12):13634-50. PubMed ID: 26872369
[TBL] [Abstract][Full Text] [Related]
16. Loss of NDRG2 enhanced activation of the NF-κB pathway by PTEN and NIK phosphorylation for ATL and other cancer development.
Ichikawa T; Nakahata S; Fujii M; Iha H; Morishita K
Sci Rep; 2015 Aug; 5():12841. PubMed ID: 26269411
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA 744-3p promotes MMP-9-mediated metastasis by simultaneously suppressing PDCD4 and PTEN in laryngeal squamous cell carcinoma.
Li JZ; Gao W; Lei WB; Zhao J; Chan JY; Wei WI; Ho WK; Wong TS
Oncotarget; 2016 Sep; 7(36):58218-58233. PubMed ID: 27533461
[TBL] [Abstract][Full Text] [Related]
18. LINC00861 inhibits the progression of cervical cancer cells by functioning as a ceRNA for miR‑513b‑5p and regulating the PTEN/AKT/mTOR signaling pathway.
Liu H; Zhang L; Ding X; Sui X
Mol Med Rep; 2021 Jan; 23(1):. PubMed ID: 33179755
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
Martinelli E; Troiani T; D'Aiuto E; Morgillo F; Vitagliano D; Capasso A; Costantino S; Ciuffreda LP; Merolla F; Vecchione L; De Vriendt V; Tejpar S; Nappi A; Sforza V; Martini G; Berrino L; De Palma R; Ciardiello F
Int J Cancer; 2013 Nov; 133(9):2089-101. PubMed ID: 23629727
[TBL] [Abstract][Full Text] [Related]
20. Targeting PRMT5/Akt signalling axis prevents human lung cancer cell growth.
Zhang S; Ma Y; Hu X; Zheng Y; Chen X
J Cell Mol Med; 2019 Feb; 23(2):1333-1342. PubMed ID: 30461193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
